Assertio Holdings, Inc. (ASRT)

In the past six months, Assertio Holdings, Inc. stock has been impacted by several key events. Assertio reported its fourth-quarter and full-year 2025 financial results, with Q4 product sales decreasing due to the timing of channel inventory related to a Rolvedon sell-in in Q3 2025, but full-year net product sales and non-GAAP adjusted EBITDA rose. Assertio regained compliance with Nasdaq listing requirements. Assertio announced the publication of its Rolvedon® same-day dosing clinical trial. ASRT experienced significant stock price surges. Assertio announced a strategic pivot to focus on its core asset, Rolvedon, and disciplined business development in oncology therapeutics.

While explicit demand seasonality for all of Assertio Holdings, Inc.'s products and services is not detailed, there are indications of inventory-related fluctuations impacting sales reporting. A strategic sell-in of Rolvedon in the third quarter of 2025 covered subsequent demand, leading to minimal Rolvedon net product sales in the fourth quarter of 2025. The company expects quarterly demand for Rolvedon to generally align with quarterly shipments in 2026.

Assertio Holdings, Inc. is a pharmaceutical company focused on providing differentiated products to patients, primarily within the United States. The company operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. Assertio's business model involves acquiring, licensing, and commercializing branded prescription products. Its portfolio targets various therapeutic areas, including neurology, oncology, hospital care, pain, and inflammation, with key products like INDOCIN, Sympazan, CAMBIA, SPRIX, ROLVEDON, Gralise, Zipsor, and Otrexup.

Assertio Holdings, Inc. primarily provides its products to patients in the United States. The company is headquartered in Lake Forest, Illinois, United States.

Information specifically detailing Assertio Holdings, Inc.'s brand reputation is not readily available. The company's strategic shift and focus on its oncology portfolio, particularly Rolvedon, could be seen as an effort to strengthen its market position and, by extension, its reputation within that specialized area.

Assertio Holdings, Inc. has a mix of institutional and individual owners. Major Institutional Owners include Nantahala Capital Management, LLC, Vanguard Group Inc, Renaissance Technologies Llc, Edgewood Management Llc, BlackRock, Inc., Susquehanna International Group, Llp, Geode Capital Management, Llc, CM Management, LLC, Citadel Advisors Llc, and Millennium Management Llc. Major Individual Owners (Insiders) include Gavin Molinelli, Biovail Laboratories Inc, Kevin C. Tang, James A. Schoeneck, Arthur J. Higgins, Peter D. Staple, John N. Shell, William McKee, and Julian N. Stern. Gavin Molinelli is the largest individual shareholder.